systems, including assays measuring synthesis of full-length protein in mdx myotubes, mdx mice, and Cftr Ϫ/Ϫ transgenic mice (2, 3) . These tests eliminated inactive chemical scaffolds and identified PTC124. Subsequently, PTC124 demonstrated nonsense suppression activity in cystic fibrosis and Duchenne muscular dystrophy patients (2, 4) . These independent confirmations in validated suppression assays are to be contrasted with Auld et al.'s (1) use of a Renilla luciferase reporter that was an unsuitable and misinterpreted gauge of nonsense suppression because it failed to respond appreciably to the established nonsense-suppressing aminoglycoside, G418.
Although Auld and colleagues demonstrated elsewhere (5, 6) that luciferase IC 50 activities vary widely with different luciferase substrates, in their recent PNAS article they presented only data from the Steady-Glo substrate (1). However, Steady-Glo has a 60-fold lower IC 50 for PTC124 than BrightGlo, the substrate we used (2) (Fig. 1A) . Detection of nonsense suppression at 30 nM PTC124, well below the IC 50 value of Bright-Go, indicates that the FLuc suppression activity we reported (2) cannot be due to enzyme inhibition. Auld et al. (1) also utilized transient transfections, whereas we used stable cell lines (2). Using transient transfections and both FLuc substrates, we found that PTC124 treatment recapitulated our previously reported Bright-Glo results (2) (Fig. 1B) . However, consistent with the potent PTC124 IC 50 with Steady-Glo, no luciferase activity was observed at any concentrations tested (Fig. 1B) .
PTC124's activity in animal models and clinical trials, and the failure of Auld et al. (1) 
